

The Guam Board of Examiners for Pharmacy

Guam Board of Examiners for Pharmacy Regular Board Meeting

Thursday, June 19, 2025 at 7:30 AM

Join Zoom Meeting

<https://us06web.zoom.us/j/87324837119?pwd=MFxr4asWpheAAAl0jxHw5rv1aU2Yu3.1>

Meeting ID: 873 2483 7119

Passcode: 394351

MINUTES

Item		Discussion	Responsible Party	Reporting Timeframe	Status
I	Call to Order	Meeting Chaired by: M. Gabriel	Chair	0732	Call to Order
		A. Roll Call: GBEP Members <u>Present at HPLO Conference:</u> <input type="checkbox"/> Arthur Mariano, Treasurer <input checked="" type="checkbox"/> Jed Sana, Vice-Chair <u>Virtually Present</u> <input checked="" type="checkbox"/> Angelina Eustaquio, Secretary <input checked="" type="checkbox"/> Melissa Gabriel, Chairperson	Chair	0732	Quorum Established
		B. Confirmation of Public Notice: Guam Daily Post: 06/12/2025 and 06/17/2025			Confirmed
II	Approval of Agenda	<i>Motion to Approve: J. Sana; 2nd: A. Eustaquio.</i>	GBEP	0733	Unanimously Approved
III	Review and Approval of Minutes	Draft Minutes dated 05/15/2025 <i>Motion to Approve: M. Gabriel; 2nd: A. Eustaquio.</i>	GBEP	0733	Unanimously Approved
IV	HPLO Administrator's Report	No Report. A. Eustaquio provided a comprehensive report following her attendance at the NABP meeting held in Florida from May 13 to 17. Representing Guam as the voting delegate, she submitted documentation of the meeting and took the opportunity to summarize key developments. Among the primary topics discussed was the upcoming introduction of the interstate privilege model, which functions similarly to the nursing compact. Under this model, licensed professionals from participating "privileged" states would be able to practice in other member states without the need for additional licensure. Participation is optional for states, and the board was informed they may soon need to consider whether to opt in. In response to a question, the speaker explained that only states participating in the compact would be able to share licensure privileges and data. Another significant discussion point at the NABP meeting involved the DSCSA and the development of a technology platform called Pulse, which is currently in beta testing. Pulse allows users to scan QR codes to verify the legitimacy and history of pharmaceutical products, aiming to combat the circulation of	B. Hattori	0734	Noted

Item		Discussion	Responsible Party	Reporting Timeframe	Status
		misbranded or substandard medications. Her report also touched on increasing concerns related to GLP-1 compounding, particularly due to its misuse by weight-loss clinics and the potential influx of questionable out-of-state pharmaceutical sources. Although this has not been a prominent issue in Guam, the delegate emphasized the importance of vigilance, especially when reviewing out-of-state licensure and operations. Additionally, A. Eustaquio voted in favor of a national initiative requiring foreign pharmacy graduates to pass both the TOEFL and the pharmacy licensure examination, a matter currently under study by a national task force. She requested that her NABP presentation and meeting dictation be included in the board's meeting minutes for reference. She concluded by noting that the next NABP meeting will be held in Boston and expressed appreciation for the opportunity to represent Guam. She also relayed a personal message of gratitude from the NABP secretary for Guam's continued attendance, noting that Puerto Rico had not attended, and mentioned her intention to step aside from attending the next meeting due to its distant location.			
V	GBEP Complaints	A. GBEP-CO-16-01 – On-going No Update. <i>Remains Tabled: M. Gabriel.</i>	GBEP	0740	On-going, Tabled
		B. GBEP-CO-24-02 – On-going No Update. <i>Remains Tabled: M. Gabriel.</i>			On-going, Tabled
VI	Old Business	A. PHARMACIES/FACILITIES/WHOLESALERS:		0740	
		1. ZimVie US Corp LLC M. Gabriel confirmed that the information had been sent to the dental board to verify whether any of the items they are wholesaling are classified as medications, and it was determined that none of them are. As a result, it was concluded that no license is required. <i>Motion to Remove Application: J. Sana; 2nd: M. Gabriel.</i>	GBEP		Unanimously Removed Application
		2. IMPRIMIS NJOF, LLC The board discussed the licensing application for IMPRIMIS NJOF, LLC, noting that the applicant had submitted a list of active state licenses, reportedly in about 20 other states. However, the matter remained tabled due to unresolved concerns stemming from FDA warning letters related to sterility and stability issues, as well as an ongoing disciplinary case with the California Board of Pharmacy. While a partial review of the submitted licenses showed that some were in good standing, not all had been fully reviewed. Members expressed discomfort with proceeding, citing unresolved violations including poor handling of patient complaints and failure to retain lot samples for retesting. Additional concern was raised regarding the lack of direct response to the FDA warning letters issued in 2023. Members emphasized that without evidence of corrective action or inspection outcomes indicating the issues had been addressed, approval of the license would be premature—especially given the gravity of the infractions involving sterile products. The board also discussed logistical concerns regarding the shipment and storage of products from New	GBEP		Tabled

Item		Discussion	Responsible Party	Reporting Timeframe	Status
		<p>Jersey, particularly if refrigeration is required.</p> <p>It was noted that IMPRIMIS has been in intermittent communication with the California Board of Pharmacy, with action letters dating back to August 21, 2024, and continuing through to February 28, 2025. While there has been correspondence, no disciplinary decision has been finalized, and their California license remains active but under accusation.</p> <p>Board members agreed that IMPRIMIS should respond directly to Guam's board to address specific concerns rather than relying solely on documentation exchanged with other regulatory bodies. It was mentioned that a representative from IMPRIMIS is willing to meet with the board, and members were open to scheduling such a meeting as a possible step forward.</p> <p><i>Remains Tabled: M. Gabriel</i></p>			
VII	New Business	PHARMACIST BY ENDORSEMENT	GBEP	0750	
		1. Laken E. Bush <i>Motion to Approve Pending MPJE & Third Board Member Signature: J. Sana; 2nd: M. Gabriel.</i>			Conditionally Approved
		B. PHARMACY TECHNICIANS:	GBEP		
		1. Elaine Marie P. Ermitanio <i>Motion to Approve Pending Third Board Member Signatures: M. Gabriel; 2nd: J. Sana.</i>			Conditionally Approved
		C. PHARMACIES/FACILITIES/WHOLESALERS:	GBEP		
		1. MD Hospital Supplies Inc <i>Motion to Approve Pending Third Board Member Signature: J. Sana; 2nd: M. Gabriel.</i>			Conditionally Approved
		2. Pharma Fusion LLC <i>Motion to Approve Pending Third Board Member Signature : J. Sana; 2nd: M. Gabriel.</i>			Conditionally Approved
		D. PHARMACY INTERN RENEWAL APPLICATIONS:	GBEP		
		1. Cynia A. Baltazar <i>Motion to Approve Pending Third Board Member Signature: J. Sana; 2nd: M. Gabriel.</i>			Conditionally Approved
		2. Jennie E. Ebidag <i>Motion to Approve Pending Third Board Member Signature: J. Sana; 2nd: M. Gabriel.</i>			Conditionally Approved
		3. Kate V. Zabala <i>Motion to Approve Pending Third Board Member Signature: J. Sana; 2nd: M. Gabriel.</i>			Conditionally Approved
E. LICENSE PORTABILITY LETTERS: <p>The board discussed the issuance of reminder letters to licensees operating under HPLO and GPAP through the Portability Act, specifically to clarify that their licenses remain valid during the period of active military orders. Draft letters had already been prepared and addressed to both the licensees and their associated employers. The discussion focused on whether a formal vote was required to authorize the distribution of these letters, with members uncertain about precedent for voting on similar correspondence. Previous examples, such as the intern letter and notices related to changes in federal law, had not required formal board approval, but clarification was requested to confirm the proper procedure.</p> <p>M. Gabriel indicated that no edits had been made to the draft, B. Hattori put on GBEP Board</p>	GBEP	Noted			

Item		Discussion	Responsible Party	Reporting Timeframe	Status
		<p>letterhead and addressed to the licensee's mailing address, and suggested that if no further changes were needed, the letters could be printed and sent. However, concerns about potential conflicts of interest arose, as board members were employed by the same entity as one of the licensees in question, prompting A. Eustaquio to recuse herself from the vote. This led to a broader recognition that the board may be at an impasse regarding formal approval.</p> <p>There was further discussion about the legal basis and duration of such portability licenses. It was noted that the law has not been updated since its passage, though draft regulations under review now address some of these issues. Comparisons were made to other jurisdictions, some of which explicitly require licensees continuing to practice to obtain full licensure, while Guam's regulations currently do not. A key clarification was made that the license under the Portability Act is valid for either the duration of the military orders or until the expiration of the license in the originating jurisdiction—whichever comes first—because a license cannot be endorsed from an expired credential.</p> <p>In conclusion, while the board agreed that the drafted letters accurately conveyed existing law and could likely be sent without a formal vote, further review of procedures and external practices was recommended.</p>			
VIII	Next Board Meeting	The next Guam Board of Examiners for Pharmacy Regular Session Meeting is scheduled for July 17, 2025 at 7:30 a.m	GBEP	0805	Set Date
IX	Adjournment	<i>Motion to Adjourn: J. Sana; 2nd : M. Gabriel.</i>	GBEP	0807	Adjourned

Minutes Drafted by: FLAME TREE Freedom Center, Inc.

Date Submitted:

Submitted by the GBEP Secretary:

Date:

Approved by the GBEP with or without changes:

Date: 7/17/25

Certified by or Attested by the Chairperson:

Date: 7/17/25